Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

Germany’s Merck KGaA (DE:MRK) is in advanced talks to buy U.S.-based SpringWorks Therapeutics (SWTX) for roughly $3.5 billion, aiming to boost ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

Merck KGaA (MKGAY) reacted to press reports and confirmed late-stage discussions with SpringWorks Therapeutics (SWTX) on a potential ...

Scores of FDA employees are searching for an exit from an agency in turmoil, especially staffers tasked with reviewing drug ...

Germany's Merck is on the verge of a billion-euro takeover of US biopharmaceutical company Springworks Therapeutics, with the ...

Gilead Sciences reports profits but mixed revenue; Merck is in talks to acquire SpringWorks for $3.5 billion; measles cases ...

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...

Shares of SpringWorks Therapeutics climbed after The Wall Street Journal reported that Germany's Merck KGaA is nearing a $3.5 billion deal for the U.S. biopharmaceutical company. SpringWorks stock ...

Recent health news highlights financial and strategic developments in major pharmaceutical companies like Gilead and Merck, ...